Table 4 Variation and reduction of chemotherapy (CTX)
Induction CTX | No. of patients/total no. (%) | |
|---|---|---|
On schedule | Drug withdrawal | |
Gemcitabine 1000Â mg/m2 | 5/15 (33.3) | 4/15 (26.7) |
Gemcitabine 800Â mg/m2 | 1/15 (6.7) | 1/15 (6.7) |
Gemcitabine and nab-paclitaxel | 0 | 4/15 (26.7) |
Concurrent CTX | No. of patients/total no. (%) | |
|---|---|---|
On schedule | Drug withdrawal | |
Gemcitabine 1000Â mg/m2 | 3/15 (20) | 1/15 (6.7) |
Gemcitabine 800Â mg/m2 | 2/15 (13.3) | 5/15 (33.3) |
Gemcitabine 650Â mg/m2 | 0 | 2/15 (13.3) |
Gemcitabine 600Â mg/m2 | 0 | 2/15 (13.3) |
Adjuvant CTX | No. of patients/total no. (%) | |
|---|---|---|
On schedule | Drug withdrawal | |
Gemcitabine 1000Â mg/m2 | 2/14 (14.2) | 2/14 (14.2) |
Gemcitabine 800Â mg/m2 | 1/14 (7.1) | 5/14 (35.7) |
Gemcitabine 650Â mg/m2 | 0 | 2/14 (14.2) |
Gemcitabine 600Â mg/m2 | 0 | 1/14 (7.1) |
Gemcitabine and nab-paclitaxel | 0 | 1/14 (7.1) |